Get informed when a big investor buys or sells
+ Follow1.53%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for TNPH is 1.53%. That is below the sector sector average of 10.27%. Investors often review this figure alongside Tian'an Pharmaceutical , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against its sector companies, TNPH currently prints 1.53% for ROE, while the sector average sits near 10.27%. That is roughly 85.1% below the sector mean. Large gaps often invite a closer look at Tian'an Pharmaceutical , Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively Tian'an Pharmaceutical , Ltd. converts resources into returns. At 1.53%, TNPH may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting TNPH's ROE (1.53%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.